Sugi Predict

Sugi Predict / Targets / CYP2U1

CYP2U1

Cytochrome P450 2U1 (Long-chain fatty acid om · Q7Z449 · CYP2U1 on Sugi Atlas →

6,501 patent compounds predicted against CYP2U1, 4,138 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL2954516 SCHEMBL2954516 0.70 3/20
SCHEMBL2753072 SCHEMBL2753072 0.56 3/20
SCHEMBL2752346 SCHEMBL2752346 0.52 3/20
SCHEMBL2752131 SCHEMBL2752131 0.52 3/20
SCHEMBL1165314 SCHEMBL1165314 0.47 3/20
SCHEMBL971260 SCHEMBL971260 0.42 3/20
SCHEMBL2749440 SCHEMBL2749440 0.42 3/20
SCHEMBL2752725 SCHEMBL2752725 0.41 3/20
SCHEMBL2091704 SCHEMBL2091704 0.41 3/20
SCHEMBL971261 SCHEMBL971261 0.40 3/20
Trifluoroacetic Acid Trifluoroacetic Acid (SCHEMBL2566375) 0.90 2/20
Trifluoroacetic Acid Trifluoroacetic Acid (SCHEMBL2592428) 0.90 2/20
Trifluoroacetic Acid Trifluoroacetic Acid (SCHEMBL2570005) 0.89 2/20
SCHEMBL2584612 SCHEMBL2584612 0.79 2/20
SCHEMBL2407878 SCHEMBL2407878 0.74 2/20
SCHEMBL196765 SCHEMBL196765 0.73 2/20
SCHEMBL2580241 SCHEMBL2580241 0.72 2/20
Trifluoroacetic Acid Trifluoroacetic Acid (SCHEMBL2592437) 0.70 2/20
SCHEMBL2582318 SCHEMBL2582318 0.68 2/20
SCHEMBL1180429 SCHEMBL1180429 0.67 2/20

Clinical trials — most relevant to CYP2U1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Pharmacogenetics of Nicotine Addiction Treatment PHASE3COMPLETED
Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer PHASE2COMPLETED
RBN-2397 in Combination With Pembrolizumab in Patients With SCCL PHASE1/PHASE2UNKNOWN
Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer PHASE1/PHASE2COMPLETED
Effect of Dexamethasone on CYP Enzyme Activity in Healthy Male Subjects PHASE1NOT_YET_RECRUITING
A Study of CYP-001 for the Treatment of Steroid-Resistant Acute Graft Versus Host Disease PHASE1COMPLETED
Role of CYP2B6, CYP3A4, and MDR1 in the Metabolic Clearance of Methadone PHASE1UNKNOWN
Alcohol Inhibits Drug Metabolism by Carboxylesterases PHASE1COMPLETED
Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of AFQ056 in Children With Fragile X Syndrome (FXS) PHASE1COMPLETED
Diindolylmethane in Treating Patients Undergoing Surgery for Stage I or Stage II Prostate Cancer PHASE1COMPLETED
A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies PHASE1UNKNOWN
Safety, Tolerability and Efficacy of CYP-006TK in Adults with Diabetic Foot Ulcers PHASE1COMPLETED
Cotinine Metabolism in Infants and Children PHASE1COMPLETED
Connecting Breath and Mind for CYP With Long COVID nanUNKNOWN
Rifampin and Nevirapine Interactions in Young Children nanUNKNOWN
CYP2D6 Screening for Adverse Drug Reactions to Codeine in Breast Milk nanCOMPLETED
PhaRmacOgenetics and Therapeutic Drug Monitoring In SchizophrEnia nanNOT_YET_RECRUITING
Pharmacogenomic Profiling of Pediatric Patients nanCOMPLETED
The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer nanCOMPLETED
Reduced Exposure Study Using the CHTP 1.2 With 5 Days in a Confinement Setting Followed by 85 Days in an Ambulatory Setting. nanCOMPLETED
Pharmacogenetic and Neurofunctional Brain Areas Study in Obese Patients With Binge Eating Disorder nanUNKNOWN
Cytochrome P450 2D6 (CYP 450 2D6) Genotype and Flecainide Efficacy nanUNKNOWN
Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis nanCOMPLETED
Gene Expression, Metabolomic, Microbiome, and Calcium Metabolism in Response to Varied Vitamin D Dosages nanCOMPLETED
Effects of CYP2B6 Genetic Polymorphisms on Efavirenz Pharmacokinetics nanCOMPLETED
Biomarkers of CYP2D6 and CYP3A4 Variability in Pediatrics nanCOMPLETED
Effects of Genotype on CYP2C9 Drug Interactions nanCOMPLETED
Pilot LDE225 in Locally Advanced or Metastatic BCC + Previously Tx Non-LDE225 Smoothened Inhibitors nanCOMPLETED
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care nanCOMPLETED
Developmental Regulation of Proteins Responsible for Transforming Drugs in the Body nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CYP2U1 binder may also engage these)

ProteinNameSimilarity
Q0IIF9 — 1.000 Q0IIF9 →
Q4V8D1 — 1.000 Q4V8D1 →
Q9CX98 — 0.997 Q9CX98 →
Q9QUJ1 — 0.981 Q9QUJ1 →
P11714 — 0.981 P11714 →
P56592 — 0.980 P56592 →
Q29488 — 0.980 Q29488 →
Q5RBQ1 — 0.980 Q5RBQ1 →
CYP2R1 Vitamin D 25-hydroxylase (EC 1.14.14.24) (Cyt 0.980 landscape →
P04799 — 0.979 P04799 →
Q64403 — 0.979 Q64403 →
CYP2J2 Cytochrome P450 2J2 0.979 landscape →
P15128 — 0.979 P15128 →
Q3LFT9 — 0.979 Q3LFT9 →
Q5KQT6 — 0.979 Q5KQT6 →
Q00557 — 0.979 Q00557 →
O18992 — 0.978 O18992 →
P24456 — 0.978 P24456 →
Q9QYG5 — 0.978 Q9QYG5 →
Q64391 — 0.978 Q64391 →
Q64680 — 0.978 Q64680 →
P12938 — 0.978 P12938 →
CYP2D6 Cytochrome P450 2D6 0.978 landscape →
P12394 — 0.977 P12394 →
CYP4X1 Cytochrome P450 4X1 0.977 landscape →
P24453 — 0.977 P24453 →
Q64462 — 0.977 Q64462 →
P10633 — 0.977 P10633 →
Q9QYG6 — 0.977 Q9QYG6 →
Q2XNC8 — 0.976 Q2XNC8 →